The clinical, research, and social value of autopsy after any cancer death: A perspective from the Children's Oncology Group soft tissue sarcoma committee

Cancer

Volumn 118, Issue 12, 2012, Pages 3002-3009

  Spunt, Sheri L ^a   Vargas, Sara O ^b   Coffin, Cheryl M ^c   Skapek, Stephen X ^d   Parham, David M ^e   Darling, Joan ^f   Hawkins, Douglas S ^g   Keller, Charles ^h  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^f Children's Oncology Group Patient Advocacy   (United States)

^g SEATTLE CHILDREN S HOSPITAL   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT;

AUTOPSY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER TISSUE; CLINICAL RESEARCH; FAMILY; HUMAN; INFORMED CONSENT; MEDICAL EDUCATION; NOTE; OVERALL SURVIVAL; PHYSICIAN; PRIORITY JOURNAL; QUALITY CONTROL; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; TERMINAL CARE; TUMOR BIOPSY; WELLBEING;

AUTOPSY; FAMILY; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; RESEARCH;

EID: 84861878832     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26620     Document Type: Note

References (68)

1. Guarneri V, Barbieri E, Dieci MV, Piacentini F, Conte P. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. Cancer Treat Rev. 2010;36(suppl 3):S62-S66.
2. Agrawal M, Garg RJ, Kantarjian H, Cortes J. Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy? Curr Oncol Rep. 2010;12:302-313.
3. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324-1334.
4. Theissen J, Boensch M, Spitz R, et al. Heterogeneity of the MYCN oncogene in neuroblastoma. Clin Cancer Res. 2009;15:2085-2090.
5. Jin C, Jin Y, Wennerberg J, Akervall J, Dictor M, Mertens F. Karyotypic heterogeneity and clonal evolution in squamous cell carcinomas of the head and neck. Cancer Genet Cytogenet. 2002;132:85-96. (Pubitemid 34170864)
6. Orndal C, Rydholm A, Willen H, Mitelman F, Mandahl N. Cytogenetic intratumor heterogeneity in soft tissue tumors. Cancer Genet Cytogenet. 1994;78:127-137.
7. van den Hauwe L, Parizel PM, Martin JJ, Cras P, De Deyn P, De Schepper AM. Postmortem MRI of the brain with neuropathological correlation. Neuroradiology. 1995;37:343-349.
8. Bozic I, Antal T, Ohtsuki H, et al. Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci U S A. 2010;107:18545-18550.
9. Zarghooni M, Bartels U, Lee E, et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol. 2010;28:1337-1344.
10. Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res. 2006;12:6494-6501. (Pubitemid 44799723)
11. Schmidt-Kittler O, Ragg T, Daskalakis A, et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A. 2003;100:7737-7742. (Pubitemid 36760039)
12. Artale S, Sartore-Bianchi A, Veronese SM, et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol. 2008;26:4217-4219.
13. Wu JM, Halushka MK, Argani P. Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer. Hum Pathol. 2010;41:914-917.
14. Gow CH, Chang YL, Hsu YC, et al. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol. 2009;20:696-702.
15. Desai J, Shankar S, Heinrich MC, et al. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res. 2007;13(18 pt 1):5398-5405. (Pubitemid 47510366)
16. Fujii H, Yoshida M, Gong ZX, et al. Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. Cancer Res. 2000;60:114-120. (Pubitemid 30058740)
17. Jones TD, Eble JN, Wang M, Maclennan GT, Jain S, Cheng L. Clonal divergence and genetic heterogeneity in clear cell renal cell carcinomas with sarcomatoid transformation. Cancer. 2005;104:1195-1203. (Pubitemid 41278954)
18. Watzka SB, Rauscher-Potsch I, Nierlich P, et al. Concordance between epidermal growth factor receptor status in primary non-small-cell lung cancer and metastases: a post-mortem study. Eur J Cardiothorac Surg. 2010;38:34-37.
19. Liu W, Laitinen S, Khan S, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med. 2009;15:559-565.
20. Frank SA, Nowak MA. Cell biology: Developmental predisposition to cancer. Nature. 2003;422:494. (Pubitemid 36433638)
21. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER 17 Registries Research Data plus Hurricane Katrina-Impacted Louisiana Cases, November 2009 submission (1973-2007, varying) Linked to County Attributes - Total US, 1969-2007 Counties [released April 2010, based on the November 2009 submission]. Bethesda, MD: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch; 2010. Available at: http://www.seer.cancer.gov. [Accessed October 4, 2011.]
22. Raney RB, Maurer HM, Anderson JR, et al. The Intergroup Rhabdomyosarcoma Study Group (IRSG): major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols. Sarcoma. 2001;5:9-15. (Pubitemid 32319864)
23. Oberlin O, Rey A, Lyden E, et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol. 2008;26:2384-2389.
24. Guigay J. Advances in nasopharyngeal carcinoma. Curr Opin Oncol. 2008;20:264-269. (Pubitemid 351507545)
25. Jamieson S, Fuller PJ. Management of granulosa cell tumour of the ovary. Curr Opin Oncol. 2008;20:560-564.
26. Jeon DG, Song WS. How can survival be improved in localized osteosarcoma? Expert Rev Anticancer Ther. 2010;10:1313-1325.
27. Nakhleh RE, Baker PB, Zarbo RJ. Autopsy result utilization: a College of American Pathologists Q-probes study of 256 laboratories. Arch Pathol Lab Med. 1999;123:290-295. (Pubitemid 29172060)
28. Newton D, Coffin CM, Clark EB, Lowichik A. How the pediatric autopsy yields valuable information in a vertically integrated health care system. Arch Pathol Lab Med. 2004;128:1239-1246. (Pubitemid 39441645)
29. Rokoske FS, Schenck AP, Hanson LC. The potential use of autopsy for continuous quality improvement in hospice and palliative care [serial online]. Medscape J Med. 2008;10:289.
30. Sinard JH, Blood DJ. Quality improvement on an academic autopsy service. Arch Pathol Lab Med. 2001;125:237-245. (Pubitemid 32167477)
31. Zarbo RJ, Baker PB, Howanitz PJ. The autopsy as a performance measurement tool - diagnostic discrepancies and unresolved clinical questions: a College of American Pathologists Q-Probes study of 2479 autopsies from 248 institutions. Arch Pathol Lab Med. 1999;123:191-198. (Pubitemid 29124907)
32. Bayer-Garner IB, L MF, Lamps LW. Pathologists in a teaching institution assess the value of the autopsy. Arch Pathol Lab Med. 2002;126:442-447. (Pubitemid 34286809)
33. Rosenbaum GE, Burns J, Johnson J, Mitchell C, Robinson M, Truog RD. Autopsy consent practice at US teaching hospitals: results of a national survey. Arch Intern Med. 2000;160:374-380. (Pubitemid 30075220)
34. Shojania KG, Burton EC, McDonald KM, Goldman L. Changes in rates of autopsy-detected diagnostic errors over time: a systematic review. JAMA. 2003;289:2849-2856. (Pubitemid 37430121)
35. Tavora F, Crowder CD, Sun CC, Burke AP. Discrepancies between clinical and autopsy diagnoses: a comparison of university, community, and private autopsy practices. Am J Clin Pathol. 2008;129:102-109. (Pubitemid 352038600)
36. Veress B, Alafuzoff I. A retrospective analysis of clinical diagnoses and autopsy findings in 3,042 cases during 2 different time periods. Hum Pathol. 1994;25:140-145. (Pubitemid 24079633)
37. Pastores SM, Dulu A, Voigt L, Raoof N, Alicea M, Halpern NA. Premortem clinical diagnoses and postmortem autopsy findings: discrepancies in critically ill cancer patients [serial online]. Crit Care. 2007;11:R48.
38. Buckner T, Blatt J, Smith SV. The autopsy in pediatrics and pediatric oncology: a single-institution experience. Pediatr Dev Pathol. 2006;9:374-380. (Pubitemid 44433376)
39. Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica. 2006;91:986-989. (Pubitemid 44023159)
40. Koszyca B, Moore L, Toogood I, Byard RW. Is postmortem examination useful in pediatric oncology? Pediatr Pathol. 1993;13:709-715. (Pubitemid 23343977)
41. Nigro JF, Gresik MV, Fernbach DJ. Value of the postmortem examination in a pediatric population with leukemia. J Pediatr. 1990;116:350-354. (Pubitemid 20109784)
42. Brieva-Ruiz L, Diaz-Hurtado M, Matias-Guiu X, Marquez-Medina D, Tarragona J, Graus F. Anti-Ri-associated paraneoplastic cerebellar degeneration and breast cancer: an autopsy case study. Clin Neurol Neurosurg. 2008;110:1044-1046.
43. Dammas S, Patz EF Jr, Goodman PC. Identification of small lung nodules at autopsy: implications for lung cancer screening and overdiagnosis bias. Lung Cancer. 2001;33:11-16. (Pubitemid 32586776)
44. Reed E, Zerbe CS, Brawley OW, Bicher A, Steinberg SM. Analysis of autopsy evaluations of ovarian cancer patients treated at the National Cancer Institute, 1972-1988. Am J Clin Oncol. 2000;23:107-116.
45. Welch HG, Black WC. Using autopsy series to estimate the disease "reservoir" for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med. 1997;127:1023-1028. (Pubitemid 27516615)
46. Haas GP, Delongchamps NB, Jones RF, et al. Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst. 2007;99:1484-1489.
47. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 2004;64:9209-9216. (Pubitemid 39665537)
48. Alaeddini R, Walsh SJ, Abbas A. Forensic implications of genetic analyses from degraded DNA - a review. Forensic Sci Int Genet. 2010;4:148-157.
49. Lunetta P, Sippel H. Positive prostate-specific antigen (PSA) reaction in post-mortem rectal swabs: a cautionary note. J Forensic Leg Med. 2009;16:397-399.
50. Broniscer A, Baker JN, Baker SJ, et al. Prospective collection of tissue samples at autopsy in children with diffuse intrinsic pontine glioma. Cancer. 2010;116:4632-4637.
51. Embuscado EE, Laheru D, Ricci F, et al. Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biol Ther. 2005;4:548-554. (Pubitemid 41351229)
52. Rankin J, Wright C, Lind T. Cross sectional survey of parents' experience and views of the postmortem examination. BMJ. 2002;324:816-818. (Pubitemid 34280733)
53. Millar T, Walker R, Arango JC, et al. Tissue and organ donation for research in forensic pathology: the MRC Sudden Death Brain and Tissue Bank. J Pathol. 2007;213:369-375. (Pubitemid 350206508)
54. Start RD, Sherwood SJ, Kent G, Angel CA. Audit study of next of kin's satisfaction with clinical necropsy service. BMJ. 1996;312:1516-1516.
55. Souza VL, Rosner F. Increasing autopsy rates at a public hospital. J Gen Intern Med. 1997;12:315-317. (Pubitemid 27212778)
56. Burton EC, Phillips RS, Covinsky KE, et al. The relation of autopsy rate to physicians' beliefs and recommendations regarding autopsy. Am J Med. 2004;117:255-261. (Pubitemid 39092719)
57. Hull MJ, Nazarian RM, Wheeler AE, Black-Schaffer WS, Mark EJ. Resident physician opinions on autopsy importance and procurement. Hum Pathol. 2007;38:342-350. (Pubitemid 46096561)
58. Oluwasola OA, Fawole OI, Otegbayo AJ, Ogun GO, Adebamowo CA, Bamigboye AE. The autopsy: knowledge, attitude, and perceptions of doctors and relatives of the deceased. Arch Pathol Lab Med. 2009;133:78-82.
59. Sanner M. A comparison of public attitudes toward autopsy, organ donation, and anatomic dissection. A Swedish survey. JAMA. 1994;271:284-288. (Pubitemid 24030755)
60. Connell CM, Avey H, Holmes SB. Attitudes about autopsy: implications for educational interventions. Gerontologist. 1994;34:665-673. (Pubitemid 24313613)
61. Burton JL, Underwood J. Clinical, educational, and epidemiological value of autopsy. Lancet. 2007;369:1471-1480. (Pubitemid 46635757)
62. Tsitsikas DA, Brothwell M, Chin Aleong JA, Lister AT. The attitudes of relatives to autopsy: a misconception. J Clin Pathol. 2011;64:412-414.
63. Campbell CS. Religion and the body in medical research. Kennedy Inst Ethics J. 1998;8:275-305. (Pubitemid 128445239)
64. Gatrad AR. Muslim customs surrounding death, bereavement, postmortem examinations, and organ transplants. BMJ. 1994;309:521-523. (Pubitemid 24261230)
65. Perkins HS, Supik JD, Hazuda HP. Autopsy decisions: the possibility of conflicting cultural attitudes. J Clin Ethics. 1993;4:145-154.
66. Doyal L. Clinical ethics committees and the formulation of health care policy. J Med Ethics. 2001;27(suppl 1):i44-i49. (Pubitemid 32294081)
67. Kass NE, Pronovost PJ. Quality, safety, and institutional review boards: navigating ethics and oversight in applied health systems research. Am J Med Qual. 2011;26:157-159.
68. Committee on Care at the End of Life; Field, MJ, Cassel CK, eds. Approaching Death: Improving Care at the End of Life. Bethesda, MD: Institute of Medicine, 1997.